Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | BCL9 | O00512 | 3/20 | 0.35 |
| ▸ | CTNNB1 | P35222 | 3/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 4/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116104 | 1.00 | HSD11B1 (0.37) | HSD11B1PARP1USP30CYP2C9NPC1 | |
| SCHEMBL6610559 | 0.95 | PARP1 (0.37) | HSD11B1PARP1USP30CYP2C9NPC1 | |
| SCHEMBL6610557 | 0.95 | PARP1 (0.37) | HSD11B1PARP1USP30CYP2C9NPC1 | |
| SCHEMBL5104915 | 0.86 | SMN1; SMN2 (0.43) | USP30CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5204449 | 0.86 | SMN1; SMN2 (0.43) | USP30CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5117318 | 0.81 | SMN1; SMN2 (0.43) | USP30CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5117324 | 0.81 | SMN1; SMN2 (0.43) | USP30CYP2C9NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5116166 | 0.71 | APP (0.42) | HSD11B1PARP1USP30NPC1RAB9A | |
| SCHEMBL22589283 | 0.70 | CHRM2 (0.51) | CYP2C9NPC1RAB9ASMN1; SMN2CYP3A4 | |
| SCHEMBL7672577 | 0.69 | SMN1; SMN2 (0.46) | CYP2C9NPC1RAB9ASMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7452906-B2 | Pyridine derivatives as Raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2008-11-18 | — | — | US | disclosed |
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235843-A1 | Pyridine derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | HSD11B1 3973/4885PARP1 1152/4885USP30 2793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.